Occurrence of serum antibodies against wheat alpha-amylase inhibitor 0.19 in celiac disease.

Occurrence of serum antibodies against wheat alpha-amylase inhibitor 0.19 in celiac disease. Physiol Res. 2018 May 10; Authors: Sánchez D, Štěpánová-Honzová S, Hospodková M, Hoffmanová I, Hábová V, Halada P, Tlaskalová-Hogenová H, Tučková L Abstract The alcohol-soluble fraction of wheat gluten (gliadins) induces in genetically susceptible individuals immunologically mediated celiac disease (CLD). However, gliadins and related cereal proteins are not unique foodstuff targets of CLD patients´ immune system. Non-gluten wheat alpha-amylase inhibitor 0.19 (AAI 0.19) has been found to be capable of activating human monocyte-derived dendritic cells and inducing pro-inflammatory status in intestinal mucosa of patients with celiac disease (CLD). The possible contribution of this reactivity in incomplete remission of CLD patients on a gluten-free diet (GFD) is matter of contention. In an attempt to characterize the antigenicity of AAI 0.19 in patients with active CLD, patients on a GFD and healthy controls we developed ELISA employing wheat recombinant AAI 0.19. Using this test we revealed a significant (P<0.001) elevation of IgA anti-AAI 0.19 antibodies (Ab) in patients with active CLD (12 out of 30 patients were seropositive) but also in CLD patients on a GFD (15/46), in contrast to healthy controls (2/59). Anti-AAI 0.19 IgG Ab levels were increased (P<0.001) only in patients with active CLD (14/30) in contrast to the co...
Source: Physiological Research - Category: Physiology Authors: Tags: Physiol Res Source Type: research